Companies: 10,795·Total market cap: $144.5T
Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYSNASDAQHealthcare● Active
$301.76
+$0.76(+0.25%)
Market Cap$8.9B
P/E Ratio
52W High$319.48
52W Low$127.99

Krystal Biotech, Inc. (KRYS) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

krys · stock forecast · 17 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 17 Wall Street analysts in the past 3 months

SellBuy

Buy

17 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
17
Hold
0
Sell
0
Strong Sell
0
Total: 17 · Buy rate: 100.0%

12-Month Price Target

High

$371

Consensus

$326

+8.5% upside

Low

$300

Median: $323 · Last Close: $300.60

The Krystal Biotech, Inc. (KRYS) analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month KRYS price target is $326.20, representing +8.5% upside from the current price of $300.60.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $326 (8.5%)

Consensus Target

$326.20

8.5% upside

High Target

$371

23.4%

Low Target

$300

-0.2%

Current Price

$300.60

as of today

Based on analyst price targets, the KRYS stock price prediction for the next 12 months ranges from $300 to $371. The consensus KRYS price forecast of $326.20 implies 8.5% upside from the current price of $300.60.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$297.551.01%

1-day model range: $296.17–$298.94. Peak: $298.94 (-1.01%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$475+58.0%
2028$640+112.9%
2029$773+157.3%
2030$870+189.5%
2031+211.3%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

57%7%36%
8Buy
1Neutral
5Sell
RSI (14)56.6Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · KRYS · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$300.88SELL
MA 10$303.12SELL
MA 20$304.02SELL
MA 50$283.22BUY
MA 100$275.80BUY
MA 200$237.11BUY
Current $KRYS · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$301.82SELL
EMA 10$301.98SELL
EMA 20$299.39BUY
EMA 50$287.77BUY
EMA 100$272.08BUY
EMA 200$245.60BUY
Current $KRYS · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-06-01
Maintains
BuyBuy
HC Wainwright & Co.2026-05-22
Maintains
BuyBuy
HC Wainwright & Co.2026-05-18
Maintains
BuyBuy
Evercore ISI Group2026-05-05
Maintains
OutperformOutperform
Citigroup2026-05-05
Maintains
BuyBuy
HC Wainwright & Co.2026-05-04
Maintains
BuyBuy
Guggenheim2026-02-25
Maintains
BuyBuy
Chardan Capital2026-02-18
Maintains
BuyBuy
Citigroup2026-02-18
Maintains
BuyBuy
Jefferies2026-02-17
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Krystal Biotech, Inc. (KRYS) stock. Of the recent 115 rating actions, 3 were upgrades and 2 were downgrades. 17 analysts currently cover KRYS.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

KRYS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$522M

↓ 38.4% YoY

Revenue Next Year

$660M

↑ 26.3% YoY

EPS This Year

$7.75

EPS Next Year

$9.71

↑ 25.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast KRYS EPS of $7.75 for the current fiscal year, based on estimates from 8 analysts. The KRYS revenue forecast is $522M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The KRYS stock forecast is supported by two independent data sources: analyst consensus ratings from 17 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KRYS price target is $326.20 (+8.5% upside), with an analyst consensus of Buy.

The KRYS short-term stock prediction for tomorrow is $297.55 (-1.01%). The KRYS stock price prediction for 2027 estimates an average of $475. The KRYS stock prediction for 2030 projects a range of $826–$915.

Krystal Biotech, Inc. trades on NASDAQ under the ticker KRYS. The KRYS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

KRYS forecast · 8 questions

According to 17 Wall Street analysts, the average 12-month KRYS price target is $326.20, with a high forecast of $371.00 and a low of $300.00. The median price target is shown in the chart above when available. This implies +8.5% potential upside from the current price of $300.60.

KRYS price targetWhat is KRYS price targetKRYS analyst price targetKRYS 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.